COFEPRIS Submission Mistakes That Delay Device Approvals

In 2025, Mexico’s COFEPRIS made major changes to its medical device regulatory process in which can produce common submission mistakes for device manufacturers. It launched abbreviated and reliance pathways for medical device sanitary registrations and opened up Good Manufacturing Practice (GMP) evidence options. COFEPRIS also committed to aggressively shorter turnaround times under this new framework.  

Key COFEPRIS Submission Mistakes

Device companies can now leverage reference market approvals from major markets, making Mexico’s new abbreviated route the primary pathway for most devices. However, even when leveraging existing approvals, experienced device manufacturers can make mistakes that delay their approvals. Actual COFEPRIS review timelines are still taking much longer than targets, and a request for information or deficiency can be a major setback. In this article, we’ll cover some of the most common submission mistakes to avoid in Mexico. 

Selecting the Wrong Registration Path

The new abbreviated pathway guidelines expanded the available Recognized Regulatory Authorities (RRAs) from three to twelve. COFEPRIS now recognizes regulatory evaluations conducted by members of the International Medical Device Regulators Forum (IMDRF) and participants in the Medical Device Single Audit Program (MDSAP).  

However, approvals in these markets do not guarantee automatic eligibility for the Abbreviated pathway. Abbreviated pathway eligibility criteria includes: 

• Identical Product Requirement: The device submitted in Mexico must be identical to the version authorized by the reference authority. Essential characteristics, components, intended use, and performance must match the approved device. All supporting quality, safety, and performance data must correspond to the reference submission. Also note that the abbreviated pathway cannot be used if there are changes to manufacturing sites, quality attributes, or primary packaging. 
• Authorization Validity: The reference authorization must have been granted within the past five years.  
• Safety status: Applicants must declare that the device has not been subject to safety alerts or warnings issued by other national authorities or the World Health Organization and has not been withdrawn from any market for safety or efficacy reasons. 
• Approval Type Limitations: Eligibility is limited to devices approved through standard regulatory review. Devices authorized through emergency pathways, judicial orders, conditional or accelerated approvals, or reliance mechanisms used by the reference authority are not eligible. 

If your application does not meet these criteria, you must use the standard registration pathway with full COFEPRIS review. 

Unverifiable or Non-Compliant GMP/QMS Evidence 

COFEPRIS recognizes certain quality management system (QMS) evidence as equivalent to Good Manufacturing Practices (GMP) certificates without requiring an additional inspection: 

• MDSAP Audit Certificate (aligned with ISO 13485) 
• ISO 13485:2016 Certification from an accredited body 
• CE Mark Certificate (European Union) 
• Free Sale Certificate (CLV) that explicitly includes a declaration of GMP compliance 

In 2025, COFEPRIS issued an official decree formalizing guidelines for documenting proof of GMP compliance. COFEPRIS validates your GMP documentation during review, but you must follow the submission guidelines so COFEPRIS reviewers can easily authenticate your documentation. 
 
Physical documents: Physical documents must be original or certified copies (documents issued by COFEPRIS may be submitted as simple copies). Foreign physical documents must be apostilled or legalized in the country of origin. Documents must also be in Spanish or English. If in another language, a translation by a certified translator is required. 
 
Electronic Documents: Documents issued electronically do not require an apostille. COFEPRIS will verify authenticity through the official site of the issuing ARN. You are responsible for providing the detailed access path (URL) and, if necessary, the corresponding username and password to the official site. 
 
If COFEPRIS is unable to verify the authenticity of a document electronically, you may be required to present the original document or a certified copy in person. All of the requirements for physical documents will apply for secondary validation. 

Manufacturer Identity Mismatch or Inconsistencies 

COFEPRIS submission mistakes include circumstances in which any aspect of device manufacturing is outsourced or contracted can create opportunities for error. Many device companies outsource manufacturing, assembly, or materials sourcing, but it is essential that the relationship architecture is well illustrated, and that quality oversight of all contract manufacturers is documented. 

COFEPRIS has established the following definitions for legal manufacturers and real manufacturers: 

The legal manufacturer: is the entity ultimately responsible for safety, performance, quality, and regulatory compliance, even if production is outsourced.  

The real manufacturer: is the entity that physically manufactures or assembles the device, which may be a subsidiary or a contractor operating under a quality or maquila agreement. 

Any discrepancies regarding manufacturer’s identities can trigger a deficiency, including the device labeling. Mexican labeling standards require the manufacturer name (legal manufacturer) and the device’s country of origin to appear on the label. If the real manufacturer is in a different country than the legal manufacturer, the real manufacturer location should appear on the label.  

The distinction between the legal and real manufacturer must be clearly established and consistent throughout the filing. Legal manufacturers may need to include an explanatory letter that outlines its relationships with suppliers, including real or contract manufacturers. In the case of contract manufacturers, your submission should also include your quality or manufacturer (maquila) agreement with the real manufacturer. 

QMS evidence or certificates in support of your application need to confirm the manufacturing sites’ QMS compliance. It’s worth noting again that the manufacturing site must match the site in your reference market documentation if you intend to use the Abbreviated pathway. Even if you can provide acceptable proof of GMP compliance for your new real manufacturer, you cannot use the Abbreviated pathway if your manufacturing site has changed. 

Translation Errors and IFU Inconsistencies 

COFEPRIS now accepts submission documentation in English or Spanish but labeling and instructions for use (IFU) must still be provided in Spanish for the end user. The IFU must match the approved labeling and device specifications, and mismatches can trigger deficiencies. Inaccuracies or omissions can be interpreted as safety risks, even if they can be attributed to translation nuance. Your Spanish IFU should be treated as an extension of your device dossier. Inconsistent terminology between the Spanish IFU, labeling, and the technical dossier can raise questions about intended use, operating conditions, or warnings, all of which are central to your device approval.

Avoid COFEPRIS Submission Mistakes with the Right Regulatory Partner 

COFEPRIS’s updated regulatory framework offers real opportunities for faster market access in Mexico for companies who approach their submissions with precision. The 2025 reforms are meaningful steps forward, but they also introduce new eligibility criteria and documentation requirements that leave room for errors. The good news is that these mistakes are avoidable. A thorough pre-submission review, with particular attention to pathway eligibility, manufacturer identity alignment, document authentication, and IFU accuracy, can make the difference between a smooth approval and months of back-and-forth with COFEPRIS. MedEnvoy Global supports manufacturers through this process by serving as an experienced Mexico Registration Holder and regulatory partner, helping ensure submissions are aligned and compliant. Please reach out if you require assistance by clicking here, and for more information about our consulting services, click here.